The primary objective of the RECAP Study Program is to investigate the role played by
conscious experience in the antidepressant effects of the psychedelic agent psilocybin. This
pilot dosing study (PILOT RECAP) is designed to determine the optimal dose of midazolam that
allows a psychedelic experience to occur while inducing amnesia for the experience. This is
an essential step required for subsequent evaluation of the role of memory for the
psychedelic experience in the antidepressant effects of psilocybin in the full RECAP study.